Lidocaine for postoperative pain after cardiac surgery: a systematic review

Michael R. Boswell¹, Rajat N. Moman¹, Melissa Burtoft¹, Harrison Gerdes¹, Jacob Martinez¹, Danielle J. Gerberi², Erica Wittwer¹, M. Hassan Murad³ and W. Michael Hooten¹,4*

Abstract

Objective: Lidocaine is one of the most widely used local anesthetics with well-known pharmacological properties. The purpose of this systematic review is to investigate the effects of lidocaine on postoperative pain scores and recovery after cardiac surgery.

Methods: A comprehensive database search was conducted by a reference librarian for randomized clinical trials (RCT) from January 1, 1980 to September 1, 2019. Eligible study designs included randomized controlled trials of lidocaine for postoperative pain management in adults undergoing cardiac surgery. After removal of duplicates, 947 records were screened for eligibility and 3 RCTs met inclusion criteria.

Results: Sources of bias were identified in 2 of 3 RCTs. Lidocaine was administered intravenously, topically, and intrapleurally. Key findings included [1] 2% lidocaine placed topically on chest tube prior to intraoperative insertion was associated with significantly lower pain scores and lower cumulative doses of fentanyl; and [2] 2% lidocaine administered intrapleurally was associated with significantly lower pain scores and significant improvements in pulmonary mechanics. Lidocaine infusions were not associated with significant changes in pain scores or measures of recovery. No significant associations were observed between lidocaine and overall mortality, hospital length of stay or ICU length of stay. No data were reported for postoperative nausea and vomiting or arrhythmias.

Conclusions: Due to the favorable risk profile of topical lidocaine and the need for further advancements in the postoperative care of adults after cardiac surgery, topically administered lidocaine could be considered for incorporation into established postoperative recovery protocols.

Keywords: Systematic review, Lidocaine, Meta-analysis, Cardiac surgery, Postoperative pain

Introduction

Cardiac surgery, compared to other major surgical procedures, is associated with considerable pain [1], and research aimed at optimizing postoperative pain management is ongoing [2]. Pain after cardiac surgery is most severe on postoperative day (POD) 1 and 2 [3, 4]. Although pain diminishes throughout the postoperative period, nearly half of patients continue to report severe pain at rest on POD 4 [5]. The location of pain changes throughout the postoperative period. During the early postoperative course, the majority of severe pain involves the primary operative site but, after POD 2, other important areas of pain include the lower extremities, due to vein extraction, and shoulders [4, 5]. Coughing, moving, turning, deep breathing and using incentive spirometry are associated with pain through POD 4 and POD 6 [3, 5]. Effective management of acute postoperative pain is important because greater acute pain severity during the postoperative period is associated with development of chronic postoperative pain [6, 7].

* Correspondence: hooten.william@mayo.edu
¹Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55902, USA
²Division of Pain Medicine, Mayo Clinic, Rochester, MN, USA

Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
In the Enhanced Recovery After Surgery Society recommendations for perioperative cardiac surgery care, multimodal opioid-sparing pain management plans are strongly recommended (Class I recommendation) [8]. Multimodal pain management after cardiac surgery frequently incorporates local anesthetics administered intravenously, infiltrated perineurally, or infused into the epidural space [9]. Lidocaine is widely used in the perioperative period but, unlike other local anesthetic drugs, topical formulations of lidocaine are readily available and it can be safely administered as an intravenous infusion which expands the therapeutic uses of this particular drug. However, the effects of lidocaine on postoperative pain and recovery after cardiac surgery have not been systematically reviewed. Thus, the primary objective of this systematic review is to investigate the effects of lidocaine on postoperative pain scores after cardiac surgery. Secondary objectives include investigating the effects of lidocaine on postoperative pain scores after cardiac surgery. Secondary objectives include investigating the effects of lidocaine on postoperative opioid consumption, rate of postoperative nausea and vomiting, and hospital length of stay. In addition, adverse effects associated with lidocaine, including arrhythmias and all-cause mortality, will be documented.

Methods

Study protocol

Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines [10] were followed. An a priori protocol was followed. The trial was registered in the PROSPERO database (CRD42020152017) [11].

Search strategy

The medical literature was searched by a medical reference librarian for content about the postoperative effects of lidocaine after cardiac surgery. The search strategies were created using a combination of keywords and standardized indexing terms. A comprehensive search of databases from January 1, 1980 to September 1, 2019 was conducted. Manuscripts were restricted to the English language. Searches were executed in ClinicalTrials.gov, Ovid EBM Reviews, Ovid Embase, Ovid Medline, Scopus, and Web of Science. Search strategies are presented in Additional file 1: Appendix A.

Study selection process

Study inclusion criteria included (1) randomized clinical trials (RCTs); (2) studies that assessed postoperative pain and recovery in patients after cardiac surgery; (3) studies that assessed the use of topical, intravenous, or other routes of lidocaine administration; (4) studies from 1980 to present day; and (5) studies in the English language. Exclusion criteria included (1) studies of non-cardiac surgery patients; and (2) non-human studies.

Results

Characteristics of included studies

A flow diagram of the study selection process is depicted in Fig. 1. Three studies [23–25] met inclusion and exclusion criteria (Table 1), and were included in the qualitative analysis. All studies were RCTs involving patients who underwent a median sternotomy for coronary artery bypass graft surgery. The route of lidocaine administration in these studies included an intravenous infusion [23], topical application [24] and intrapleural injection [25]. The primary outcome for each of these studies was postoperative pain scores measured using a visual analogue scale (VAS) or numeric rating scale (NRS) assessed at time intervals ranging from 4 h to 4 days postoperatively. Studies that used a VAS presented...
patients with a 10 cm visual scale labeled either 0 to 10 [23] or 0 to 100 [24]; a score of 0 denoted no pain and the maximum scores of 10 or 100 denoted the worst possible pain. In the study that used the NRS [25], pain was rated on a scale between 0 to 10 where 0 denoted no pain and 10 denoted the worse possible pain. One study [23] reported postoperative pain scores at hours 4, 8 and 16. All three studies [23–25] reported postoperative pain scores at hours 24 and 48. Two studies [23, 24] reported mortality data and one study [23] reported

Table 1  Study characteristics

| Author       | Study design                      | Participants | Intervention vs. control | Timeline                                                                 | Primary outcome                                                                                               | Secondary outcome                                                                                   | Follow-up period | Dropouts | Risk of bias |
|--------------|-----------------------------------|--------------|--------------------------|-------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|------------------|----------|--------------|
| Insler, 2009 | Randomized double-blind placebo-controlled trial | n = 100, MS for CABG; mean age 63 years; 72% male | IV lidocaine infusion (n = 44) vs. placebo substitute (n = 45) | Anesthesia induction until either ICU dismissal or PO hour 48            | VAS pain score at PO hours 4, 8, 16, 24, 48, 96                                                              | ICU hemodynamics; MI; extubation time; sedation score; PO fentanyl, midazolam, propranolol doses; ICU and hospital length of stay | ICU dismissal or PO hour 48 | 11       | Some concerns |
| Kang, 2014   | Randomized placebo-controlled trial | n = 45; MS for CABG; mean age 68 years; 67% male | Topical lidocaine 2% gel on chest tubes (n = 22) vs. normal saline placebo (n = 23) | Single application with intraoperative insertion of chest tubes       | VAS pain scores at extubation and POD 1, 2, 3                                                             | Cumulative PCA fentanyl PCA; number of PCA button pushes; chest tube worse site of pain              | POD 7            | 3        | Low         |
| Mashaqi, 2018| Randomized double-blind placebo-controlled trial | n = 40; MS for CABG; age and sex not reported | Intrapleural 12 mL 2% lidocaine (n = 20) vs. 12 mL 0.9% saline solution placebo (n = 20) | Single injection on POD 1 and 2; administered via left-sided double-lumen chest tube | NRS pain scores on POD 1 and POD 2                                                                          | FEV1 before and after injections on POD 1 and POD 2                                                | POD 2            | 0        | High        |

CABG coronary artery bypass graft, MS median sternotomy, IV intravenous, ICU intensive care unit, MI myocardial infarction, POD postoperative day, PO postoperative, VAS visual analog scale, NRS numerical analog scale, PCA patient controlled analgesia, FEV1 forced expiratory volume at one second
intensive care unit and hospital length of stay. Data about postoperative nausea and vomiting, and arrhythmias were not reported. Other outcomes varied between studies and included (1) cumulative postoperative opioid dose, (2) benzodiazepine dose; (3) beta-blocker dose; (4) frequency of patient controlled analgesia (PCA) button pushes; (5) proportion of patients reporting chest tubes as the most painful site; (6) postoperative day of chest tube removal; (7) mean forced expiratory volume at 1 sec (FEV1) on POD 1; (8) sedation scores; (9) occurrence of postoperative myocardial infarction; and (10) time to extubation.

Risk of Bias evaluation
The RoB2 was used to assess bias in the 3 studies. One study demonstrated a high risk of bias [25], one study had some concerns for bias [23], and one study had a low risk of bias [24]. In the study that had a high risk of bias [25], information about the method of randomization or blinding were not included. In the study that had some concerns for bias [23], potential reporting biases were identified because greater than 10% of patients were excluded for protocol deviations, excessive bleeding, supratherapeutic lidocaine serum levels, and use of multiple ionotropic medications.

Pain intensity
All three studies reported pain intensity using the VAS [23, 24] or NRS [25]. Postoperative pain scores were reported across a range of time intervals spanning 4 h to 4 days.

In the Insler et al. study [23] patients were randomized to receive an intravenous lidocaine or placebo infusion from induction of general anesthesia to postoperative hour 48 or intensive care unit (ICU) dismissal, whichever came first. The VAS was assessed at hours 4, 8, 16, 24, 48, and 96 after ICU admission. No statistically significant difference in pain scores were observed between the lidocaine and control groups [23]. The certainty in evidence was very low due to severe imprecision.

In the Kang et al. study [24] patients were randomized to receive an application of topical 2% lidocaine gel or normal saline as a placebo on chest tubes prior to intraoperative placement. At the time of extubation and on POD 1, 2 or 3 patients in the lidocaine group reported significantly lower chest tube-related pain scores compared to the placebo group. Similarly, at the time of extubation and on postoperative day 7, the proportion of patients who reported the chest tube site as the “most painful site” was significantly less in the lidocaine group compared to the placebo group. The certainty in evidence was low due to imprecision.

In the Mashaqi et al. study [25], patients were randomized to receive 12 ml of 2% lidocaine intrapleurally or a saline solution placebo on POD 1 and 2. Mean pain scores were significantly different pre- and post-intrapleural injection in the lidocaine group compared to the placebo group on POD 1 and 2. The certainty in evidence was very low due to severe imprecision.

Opioid-sparing effects
Two studies [23, 24] reported the cumulative opioid dose during the postoperative hospital stay. Insler et al. [23] reported the cumulative postoperative fentanyl dose administered via a nurse-driven protocol. No significant group difference in cumulative fentanyl dose was observed between the lidocaine and placebo groups.

Kang et al. [24] reported the cumulative postoperative fentanyl dose administered via PCA and the number of PCA button pushes was also recorded. The cumulative fentanyl dose was significantly lower in the group that received topical lidocaine on chest tubes prior to insertion compared to placebo. Similarly, the number of PCA button pushes was significantly lower in the group that received topical lidocaine compared to placebo.

Mortality and hospital length of stay
Two studies reported mortality data. Insler et al. [23] reported one death in the lidocaine infusion group that was determined not to be related to lidocaine, and Kang et al. [24] reported no deaths attributed to “surgical mortality.” In the Insler et al. [23] study, data were reported about ICU and hospital length of stay but no between-group differences in either measure were observed.

 Forced expiratory volume at 1 s
In the Mashaqi et al. [25] study, patients randomized to the intrapleural lidocaine group experienced statistically significant improvements in FEV1 compared to placebo on POD 1 and 2.

Discussion
The key findings of this systematic review include (1) 2% lidocaine placed topically on chest tubes prior to intraoperative insertion was associated with significantly lower pain scores and lower cumulative doses of fentanyl (certainty in evidence low); and (2) 2% lidocaine administered intrapleurally was associated with significantly lower pain scores and significant improvements in FEV1 (certainty in evidence very low). However, lidocaine infusions were not associated with significant changes in pain scores, and no significant associations were observed between postoperative lidocaine use and overall mortality, hospital length of stay or ICU length of stay (certainty in evidence very low). No data were reported for other secondary outcome measures including postoperative nausea and vomiting or arrhythmias.
The results of this study suggest that the pharmacology of topical lidocaine warrants further consideration. Lidocaine contains an amide and tertiary amine group, and the pKa is 7.9 [26]. At equilibrium, lidocaine exists as a positively charged cation and an uncharged free base. Basic conditions increase the proportion of free base that exists in solution; this is important because the free base of lidocaine penetrates the lipid containing layer of outer skin, the stratum corneum, and mucosal membranes [27]. The mean depth of skin penetration following topical application of a lidocaine and prilocaine mixture is 5 to 6 mm [28, 29], but the depth of mucosal penetration remains undetermined. The local anesthetic effects of lidocaine are produced predominately by blockade of voltage-gated sodium channels which inhibit neuronal depolarization, and the formation and propagation of action potentials [26]. In addition to the direct analgesic effects on sodium channels, lidocaine has anti-inflammatory effects. In preclinical [30–33] and clinical studies [34, 35], lidocaine reduces macrophage activation and recruitment; blocks production of tumor necrosis factor and interleukin-6; and inhibits prostaglandin, thromboxane, and histamine release. The combined local anesthetic and anti-inflammatory effects of lidocaine provide an underlying pharmacological mechanism for the clinical effects observed in the Kang et al. [24], and Mashaqi et al. [25] studies.

Lidocaine infusions have been associated with improvements in postoperative pain, reduced postoperative opioid use, reduced incidence of nausea and vomiting, and reduced length of hospital stay in patients after non-cardiac surgery [36–38]. However, these favorable postoperative outcomes were not reproduced in the Insler et al. [23] study despite recruitment of an appropriately powered cohort, use of adequate lidocaine dosages for a sufficient time period, and documentation of therapeutic lidocaine serum levels. One possible explanation for these contrasting findings is the systemic inflammatory response produced by cardiopulmonary bypass [39]. This is an important consideration because cardiopulmonary bypass clearly distinguishes cardiac surgery from other major surgical procedures. Following intravenous administration, 70% of lidocaine is metabolized to N-ethylglycine [40] which is a competitive inhibitor of glycine transporter 1 [41]. This transporter regulates extracellular glycine which is the main inhibitory neurotransmitter in the spinal cord and brain stem [42]. Inhibition of glycine transporter 1 by N-ethylglycine leads to increases in serum and cerebrospinal fluid glycine concentrations, and is associated with anti-nociceptive effects in preclinical studies [41, 43]. More specifically, following systemic administration in an experimental pain model, N-ethylglycine attenuates acute inflammatory hyperalgesia [43]. However, the effects of N-ethylglycine on glycine transporter function may be disrupted by the physiological responses to cardiopulmonary bypass. In preclinical studies, intracerebral glycine concentrations were significantly elevated above baseline levels during (1) hypothermic circulatory arrest; (2) cardiopulmonary bypass reperfusion; and (3) glycine levels remained elevated for 2 to 8 h after hypothermic circulatory arrest [44–46]. Thus, in patients undergoing cardiac surgery, a key mechanism responsible for the analgesic effects of intravenous lidocaine infusions may be disrupted by the abrupt changes in glycine concentrations that occur in response to cardiopulmonary bypass.

The findings of this systematic review have implications for clinical practice and future research. First, the postoperative benefits and low risk profile of topical lidocaine suggests that intrapleural lidocaine and placement of lidocaine gel on chest tubes could be incorporated into established recovery protocols [8]. Second, topical lidocaine was associated with improvements in pain and recovery, but the findings need to be replicated in future RCTs. Third, although intravenous lidocaine infusions were not associated with significant changes in postoperative pain and recovery, future RCTs should be considered for patients receiving cardiac surgery that does not require cardiopulmonary bypass.

This review has limitations. Although a comprehensive search strategy identified 947 records, only 3 RCTs met criteria for inclusion. Thus, additional RCTs of lidocaine for postoperative pain and recovery after cardiac surgery are needed. Two of three RCTs were found to be at risk of bias [23, 25], and the certainty in evidence for all RCTs ranged from low to very low. Consequently, the results of this systematic review should be interpreted in light of the identified risk of bias, and the low to very low certainty in evidence of the three RCTs that met our inclusion and exclusion criteria. Finally, no data were reported for important secondary outcome measures including postoperative nausea and vomiting, or arrhythmias.

**Conclusions**

In conclusion, although topical lidocaine was associated with improvements in postoperative pain and measures of recovery, the results of these RCTs need to be replicated in future clinical trials. Lidocaine infusions have proven benefits for patients after non-cardiac surgery but ongoing work is needed to understand the potential impact that cardiopulmonary bypass has on the postoperative effects of lidocaine infusions. These results should be interpreted with full knowledge of the risk of
bias, and the low to very low certainty in evidence that characterize the RCTs comprising this systematic review. However, due the favorable risk profile of topical lidocaine and the need for further advancements in the postoperative care of adults after cardiac surgery [47], topically administered lidocaine could be considered for incorporation into established postoperative recovery pathways.

Abbreviations
POD: Postoperative day; RCT: Randomized clinical trial; RoB2: Cochrane’s Risk of Bias tool; VAS: Visual analogue scale; NRS: Numeric rating scale; PCA: Patient controlled analgesia; FEV1: Forced expiratory volume at one second; ICU: Intensive care unit

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13019-021-01549-0.

Additional file 1.

Acknowledgements
No acknowledgements to report.

Authors’ contributions
MB: conceptualization, methodology, formal analysis, investigation, data curation, writing original draft. RNMs: conceptualization, methodology, formal analysis, investigation, data curation, writing original draft, reviewing and editing, project administration. MB: conceptualization, methodology, formal analysis, investigation, data curation. HG: conceptualization, methodology, formal analysis, investigation, data curation. JM: conceptualization, methodology, formal analysis, investigation, data curation, statistical analysis. EW: methodology, formal analysis, investigation, data curation. NM: conceptualization, methodology, formal analysis, investigation, data curation, writing original draft, reviewing and editing. MHM: conceptualization, methodology, formal analysis, investigation, data curation, writing original draft, reviewing and editing. WMH: conceptualization, methodology, formal analysis, investigation, data curation, reviewing and editing, supervision. WM: conceptualization, methodology, formal analysis, investigation, data curation, reviewing and editing, supervision, project administration. The author(s) read and approved the final manuscript.

Funding
No funding to report.

Availability of data and materials
No supporting data to report.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
All authors have approved the manuscript for publication.

Competing interests
No competing interests to report.

Author details
1Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55902, USA. 2Mayo Clinic Library, Mayo Clinic, Rochester, MN, USA. 3Division of Preventative Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. 4Division of Pain Medicine, Mayo Clinic, Rochester, MN, USA.

References
1. Gerbershagen HJ, Aduckathil S, van Wijk AJ, et al. Pain intensity on the first day after surgery: a prospective cohort study comparing 179 surgical procedures. Anaesthesia. 2013;118(4):934–44. https://doi.org/10.1111/AN
2. Jayakumar S, Borrelli M, Milan Z, Kunst G, Whittaker D. Optimising pain management protocols following cardiac surgery: a protocol for a national quality improvement study. Int J Surg Proc. 2019;14:1–8. https://doi.org/10
3. Milgrom LB, Brooks JA, Qi R, Bunnell K, Wuestefeld S, Beckman D. Pain levels experienced with activities after cardiac surgery. Am J Crit Care. 2004;13(2):116–25. https://doi.org/10.4037/ajcpc2004.13.2.116
4. Mueller XM, Tingley F, Tevaearai HT, Revelly JP, Chiolelo R, von Segesser LK. Pain location, distribution, and intensity after cardiac surgery. Chest. 2000;118(2):391–6. https://doi.org/10.1378/chest.118.2.391
5. Lahtinen P, Koikki H, Hynynen M. Pain after cardiac surgery: a prospective cohort study of 1-year incidence and intensity. Anaesthesia. 2006;105(4):794–800. https://doi.org/10.1093/anae/206.10000.00026
6. Choiniere M, Watt-Watson J, Victor JC, et al. Prevalence of and risk factors for persistent postoperative nonanginal pain after cardiac surgery: a 2-year prospective multicentre study. CMAJ. 2014;186(7):E213–23. https://doi.org/10
7. Guimarães-Pereira L, Farinha V, Azevedo L, Abelló F, Castro-Lopes J. Persistent postoperative pain after cardiac surgery: incidence, characterization, associated factors and its impact in quality of life. Eur J Pain. 2016;20(9):1433–42. https://doi.org/10.1002/ejp.866
8. Engelman DT, Ben Ali W, Williams JB, Perrault LP, Reddy VS, Arora RC, et al. Guidelines for perioperative care in cardiac surgery: enhanced recovery after surgery society recommendations. JAMA Surg. 2019 [Epub ahead of print]; 154(8):725–66. https://doi.org/10.1001/jamapsychiatry.2019.1153
9. Noss C, Prusinkiewicz C, Nelson G, Patel PA, Augoustides JG, Gregory AJ. Enhanced recovery for cardiac surgery. J Cardiothorac Vasc Anesth. 2018;32(6):2760–70. https://doi.org/10.1053/j.jvca.2018.01.045
10. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. https://doi.org/10.1136/bmj.b2535
11. Booth A, Clarke M, Ghesri D, Moher D, Petticrew M, Stewart L. An international registry of systematic-review protocols. Lancet. 2011;377(9760):108–9. https://doi.org/10.1016/S0140-6736(10)60903-8
12. Sterne JAC, Savovic J, Page MJ, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4369. https://doi.org/10.1136/bmj.l4369
13. Murad MH. Clinical practice guidelines: a primer on development and dissemination. Mayo Clin Proc. 2017;92(3):423–33. https://doi.org/10.1016/j.mayocp.2017.01.001
14. Murad MH, Mustafa RA, Schunemann HJ, Sultan S, Santesso N. Rating the certainty in evidence in the absence of a single estimate of effect. Evid Based Med. 2017;22(3):85–7. https://doi.org/10.1016/j.ebme.2017.11.0668
15. Greenhalgh T, Robert G, Macfarlane F, Bate P, Kyriakidou O, Peacock R. Storylines of research in diffusion of innovation: a meta-narrative approach to systematic review. Soc Sci Med. 2005;61(2):417–30. https://doi.org/10.1016/j.socscimed.2004.12.001
16. Wong G, Greenhalgh T, Westhorp G, Pawson R. Development of methodological guidance, publication standards and training materials for realist and meta-narrative reviews: the ramesis (realist and meta-narrative evidence syntheses - evolving standards) project. Health Serv Deliv Res. 2014;2(30):1–278. https://doi.org/10.3310/hsdr02300
17. Hooten WM, Dvokin J, Warner NS, Pearson ACS, Murad MH, Warner DO. Characteristics of physicians who prescribe opioids for chronic pain: a meta-narrative systematic review. J Pain Res. 2019;12:2261–89. https://doi.org/10.2147/JPR.S202376
18. MacNeela P, Doyle C, O’Gorman D, Ruane N, McGuire BE. Experiences of chronic low back pain: a meta-ethnography of qualitative research. Health Psychol. 2015;34(1):63–82. https://doi.org/10.1093/107871901.2015.04051.
19. Sim J, Madden S. Illness experience in fibromyalgia syndrome: a metasynthesis of qualitative studies. Soc Sci Med. 2008;67(4):57–67. https://doi.org/10.1016/j.socscimed.2008.03.003

Received: 29 August 2020 Accepted: 24 May 2021
20. Snegurov S, Liossi C. Living with chronic low back pain: a meta-synthesis of qualitative research. Chronic Illn. 2013;9(4):283–301. https://doi.org/10.1177/1742395313476901.

21. Toye F, Seers K, Alcock N, Briggs M, Car E, Andrews JA, et al. Patients’ experiences of chronic non-malignant musculoskeletal pain: a qualitative systematic review. Br J Gen Pract. 2013;63(617):e829–41. https://doi.org/10.3399/bjgp13X675412.

22. Wong AYL, Forsi KS, Jakobsson J, Schoeb V, Kunilen C, Borglin G. Older adult’s experience of chronic low back pain and its implications on their daily life: study protocol of a systematic review of qualitative research. Syst Rev. 2018;7(1):81. https://doi.org/10.1186/s40843-018-0742-5.

23. Inselr SR, O’Connor M, Samonte AF, Bazaral MG. Lidocaine and the inhibition of postoperative pain in coronary artery bypass patients. J Cardiothorac Vasc Anesth. 1995;9(5):541–6. https://doi.org/10.1016/S1053-0770(05)80138-7.

24. Kang H, Chung YS, Choe JW, Kim SW, Park SJ, et al. Application of lidocaine jelly on chest tubes to reduce pain caused by drainage catheter after coronary artery bypass surgery. J Korean Med Sci. 2014;29(10):1398–403. https://doi.org/10.3346/jkms.2014.29.10.1398.

25. Masahaq B, Ismail I, Siemeni TT, Ruemke S, Fleissner F, Zhang R, et al. Local anesthetics delivered through pleural drainages improve pain and lung function after cardiac surgery. Thorac Cardiovasc Surg. 2018;66(2):198–202. https://doi.org/10.1055/s-0035-1558994.

26. Catterall WA, Mackie K. Chapter 22: local anesthetics. In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman: the pharmacological basis of therapeutics. 13th ed. New York, NY: McGraw-Hill; 2018.

27. Barkin RL. The pharmacology of topical anesthetics. Postgrad Med. 2013;125(sup1):17–18. https://doi.org/10.3810/pgm.2013.11.10566911.

28. Bjerring P, Arendt-Nielsen L. Depth and duration of skin anaesthesia to needle insertion after topical application of emla cream. Br J Anaesth. 1990;64(2):173–7. https://doi.org/10.1093/bja/64.2.173.

29. Wahlgren CF, Quiding H. Depth of cutaneous anaesthesia after application of a eutectic mixture of the local anesthetics lidocaine and prilocaine (emla cream). J Am Acad Dermatol. 2000;42(4):584–8. https://doi.org/10.1067/ mdj.2000.104303.

30. Lin S, Jin P, Shao C, Lu W, Xiang Q, Jiang Z, et al. Lidocaine attenuates lipopolysaccharide-induced inflammatory responses and protects against endotoxemia in mice by suppressing hifalpha-induced glycolysis. Int Immunopharmacol. 2020;80:106150. https://doi.org/10.1016/j.intimp.2019.106150.

31. Feng G, Liu S, Wang GL, Liu GJ. Lidocaine attenuates lipopolysaccharide-induced acute lung injury through inhibiting nf-kappab activation. Pharmacology. 2008;81(1):32–40. https://doi.org/10.1159/000107792.

32. Yanaghi H, Sankawa H, Saito H, Iikura Y. Effect of lidocaine on histamine release and ca2+ mobilization from mast cells and basophils. Acta Anaesthesiol Scand. 1996;40(9):1138–44. https://doi.org/10.1111/j.1399-6576.1996.tb05577.x.

33. Joo JD, Choi JW, In JH, et al. Lidocaine suppresses the increased extracellular signal-regulated kinase/cyclic amp response element-binding protein pathway and pro-inflammatory cytokines in a neuropathic pain model of rats. Eur J Anaesthesiol. 2011;28(2):106–11. https://doi.org/10.1097/EJA.0b013e32834050f8.

34. Wang HL, Yan HD, Liu YY, et al. Intraoperative intravenous lidocaine exerts a protective effect on cell-mediated immunity in patients undergoing radical hysterectomy. Mol Med Rep. 2015;12(5):2039–44. https://doi.org/10.3892/mmr.2015.4255.

35. Yardeni IZ, Beilin B, Mayburd E, Levinson Y, Bessler H. The effect of perioperative intravenous lidocaine on postoperative pain and immune function. Anesth Analg. 2009;109(5):1464–9. https://doi.org/10.1213/ANE. 0b013e3181bab1bd.

36. Weibel S, Jokinen J, Pace NL, Schnabel A, Hollmann MW, Hahnenkamp K, et al. Efficacy and safety of intravenous lidocaine for postoperative analgesia and recovery after surgery: a systematic review with trial sequential analysis. Br J Anaesth. 2016;116(6):770–83. https://doi.org/10.1093/bja/aew101.

37. Vigneault L, Turgeon AF, Cote D, et al. Perioperative intravenous lidocaine infusion for postoperative pain control: a meta-analysis of randomized controlled trials. Can J Anaesth. 2011;58(1):122–37. https://doi.org/10.1007/s12306-010-9407-0.

38. Ventrhath NT, Kennedy ED, Brady RR, Paterson HM, Speake D, Foo I, et al. Efficacy of intravenous lidocaine for postoperative analgesia following laparoscopic surgery: a meta-analysis. World J Surg. 2015;39(9):2220–34. https://doi.org/10.1007/s00268-015-3105-6.